NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GYRE

Gyre Therapeutics Inc

Jul 03 • 03:26PM ET

8.13

Dollar change +0.33
Percentage change 4.23	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN VRTX REGN GILD BMRN BIIB INCY NBIX EXEL ACAD

| Held by: VTI IWM VXF IWO SCHA VTWO SCHB AVSC RSSL TILT

Scroll to Statements

Index	RUT	P/E	169.73	EPS (ttm)	0.05	Insider Own	81.99%	Shs Outstand	87.64M	Perf Week	10.16%
Market Cap	734.33M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.16%	Shs Float	16.26M	Perf Month	-1.09%
Enterprise Value	742.20M	PEG	-	EPS next Q	0.03	Inst Own	2.90%	Short Float	8.67%	Perf Quarter	14.67%
Income	7.25M	P/S	7.30	EPS this Y	140.00%	Inst Trans	45.57%	Short Ratio	5.84	Perf Half Y	-35.78%
Sales	100.64M	P/B	10.46	EPS next Y	-	ROA	5.76%	Short Interest	1.41M	Perf YTD	-32.81%
Book/sh	0.78	P/C	24.57	EPS next 5Y	-	ROE	11.62%	52W High	19.00 -57.21%	Perf Year	-32.48%
Cash/sh	0.33	P/FCF	-	EPS past 3/5Y	- -	ROIC	10.52%	52W Low	6.11 33.06%	Perf 3Y	120.56%
Dividend Est.	-	EV/EBITDA	61.19	Sales past 3/5Y	143.36% -	Gross Margin	96.23%	Volatility	6.72% 6.68%	Perf 5Y	-43.55%
Dividend TTM	-	EV/Sales	7.37	EPS Y/Y TTM	100.48%	Oper. Margin	10.36%	ATR (14)	0.64	Perf 10Y	-98.49%
Dividend Ex-Date	Jan 13, 2023	Quick Ratio	3.19	Sales Y/Y TTM	-	Profit Margin	7.20%	RSI (14)	48.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.60	EPS Q/Q	-94.14%	SMA20	2.12%	Beta	1.74	Target Price	20.00
Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-18.82%	SMA50	-9.60%	Rel Volume	0.27	Prev Close	7.80
Employees	5	LT Debt/Eq	0.01	Earnings	May 09 BMO	SMA200	-25.76%	Avg Volume	241.47K	Price	8.13
IPO	Apr 12, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	-100.00% -22.33%	Trades		Volume	66,030	Change	4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Apr-29-21	Resumed	Stephens	Overweight	$18 → $19
Feb-10-21	Initiated	Piper Sandler	Overweight	$15
May-21-20	Initiated	Raymond James	Outperform	$20
Jan-04-19	Initiated	Oppenheimer	Outperform	$24
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy	$19 → $49
Feb-09-18	Reiterated	Chardan Capital Markets	Buy	$37.50 → $75
Feb-09-18	Reiterated	Chardan Capital Markets	Buy	$10 → $75
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy	$19
Jun-12-17	Initiated	Chardan Capital Markets	Buy	$10
Jun-06-17	Initiated	Ladenburg Thalmann	Buy	$11
Jun-30-16	Initiated	Rodman & Renshaw	Buy	$3.50

Show Previous Ratings

Jun-10-25 07:00AM	Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China (GlobeNewswire) +5.88%
May-29-25 11:34PM	Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials (Insider Monkey)
04:01PM	Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-22-25 08:57PM	Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock (GlobeNewswire) +8.10% -22.57%
04:02PM	Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock (GlobeNewswire)
04:01PM	Loading…
04:01PM	Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China (GlobeNewswire)
May-09-25 06:00AM	Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 09:15AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-01-25 08:25AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Mar-31-25 07:00AM	Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications (GlobeNewswire) -15.26%
Mar-27-25 07:00AM	Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology (GlobeNewswire)
Mar-21-25 09:14AM	Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines (SeekingAlpha)
Mar-17-25 04:15PM	Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -30.21%
Jan-06-25 07:00AM	Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors (GlobeNewswire) -9.82%
Nov-13-24 06:00AM	Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update (GlobeNewswire) -9.56%
04:05PM	Loading…
Oct-22-24 04:05PM	Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis (GlobeNewswire)
Oct-01-24 04:05PM	Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference (GlobeNewswire)
Sep-04-24 04:05PM	Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 06:00AM	Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update (GlobeNewswire)
Aug-09-24 07:00AM	Gyre Therapeutics to Present at Sidoti Virtual Investor Conference (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire)
Jul-02-24 04:05PM	Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia (GlobeNewswire)
Jun-18-24 04:05PM	Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology (GlobeNewswire) -6.33%
May-30-24 04:05PM	Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire) +9.13%
May-28-24 04:05PM	Gyre Therapeutics Announces Expected Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) -15.35%
May-09-24 04:10PM	Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-28-24 05:32AM	Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress (GuruFocus.com)
Mar-26-24 06:32AM	Gyre Therapeutics Posts Loss In 2023 (RTT News)
06:00AM	Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-24 07:00AM	Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum (GlobeNewswire)
09:04AM	Loading…
Dec-15-23 09:04AM	Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding (PR Newswire) +9.91%
Nov-13-23 07:00AM	Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting (GlobeNewswire)
Oct-30-23 12:00PM	Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split (GlobeNewswire)
Aug-23-23 12:36PM	Is Catalyst Biosciences (CBIO) Significantly Overvalued? (GuruFocus.com) +11.72%
Apr-03-23 09:01AM	Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months (Simply Wall St.)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Feb-28-23 08:00AM	Catalyst Biosciences Provides Corporate Update (GlobeNewswire) +23.75%
Dec-27-22 07:00AM	Catalyst Biosciences Completes First Steps in Reverse Merger Plan (GlobeNewswire)
Nov-16-22 05:05AM	Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021) (Simply Wall St.)
Sep-19-22 09:43AM	Bullish insiders at Catalyst Biosciences, Inc. (NASDAQ:CBIO) loaded up on US$1.2m of stock earlier this year (Simply Wall St.)
Sep-01-22 04:05PM	Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share (GlobeNewswire)
Aug-25-22 08:00AM	Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share (GlobeNewswire)
Aug-23-22 07:11AM	Catalyst Biosciences (NASDAQ:CBIO) investors are sitting on a loss of 71% if they invested three years ago (Simply Wall St.)
Aug-19-22 08:00AM	Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation (GlobeNewswire)
Aug-15-22 04:05PM	Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results (GlobeNewswire)
Aug-11-22 06:00AM	JDS1, LLC Terminates Proxy Contest at Catalysts 2022 Annual Meeting (Business Wire)
Aug-10-22 12:46PM	Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board (GlobeNewswire)
Aug-03-22 08:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote FOR All of the Companys Nominees on the WHITE Proxy Card (GlobeNewswire)
Aug-01-22 08:30AM	Catalyst Biosciences Publishes New Investor Presentation (GlobeNewswire)
07:30AM	Catalyst Biosciences Announces Support from Largest Single Stockholder (GlobeNewswire)
Jul-22-22 12:21PM	JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders (Business Wire)
Jul-19-22 08:00AM	Catalyst Biosciences Sends Letter to Stockholders (GlobeNewswire)
Jul-14-22 09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-06-22 08:00AM	Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling (GlobeNewswire)
Jun-29-22 08:00AM	Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders (GlobeNewswire) +13.25%
Jun-28-22 09:40AM	Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year? (Zacks) -5.03%
May-26-22 11:03AM	The Petri Dish: NIH gives $68M to Pfizer-partnered AI startup (American City Business Journals) -22.38%
May-23-22 09:57AM	Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex (Benzinga) +234.21%
08:30AM	Catalyst Biosciences Sells Complement Portfolio for $60 Million (GlobeNewswire)
May-09-22 08:30AM	Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results (GlobeNewswire) -11.42%
Apr-08-22 09:57AM	Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely (Simply Wall St.) -7.26%
Mar-31-22 08:00AM	Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-15-22 05:00PM	Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIOs Complement Portfolio in Ophthalmology (GlobeNewswire) +9.50%
Feb-17-22 08:00AM	Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives (GlobeNewswire) +6.40%
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com)
Jan-25-22 08:00AM	Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency (GlobeNewswire) -7.05%
Jan-12-22 12:00PM	Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-20-21 07:51PM	Penny Stocks to Buy Using Technical Analysis for January 2022 (Investopedia)
Dec-11-21 11:59AM	Timothy P. Lynchs Stonepine Capital Portfolio: Top 10 Healthcare Stocks (Insider Monkey)
Nov-22-21 08:00AM	Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-12-21 09:54AM	Catalyst Biosciences Down 40% After Announcing MarzAA Development Halt (Investing.com) -41.84%
09:24AM	What Is Happening With Catalyst Biosciences Shares Today? (Benzinga)
07:00AM	Catalyst Biosciences Announces Change in Corporate Strategy (GlobeNewswire)
Oct-29-21 08:00AM	Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences (GlobeNewswire)
Oct-28-21 03:05PM	Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +5.03%
Oct-13-21 04:05PM	Catalyst Biosciences Announces Chief Financial Officer Transition (GlobeNewswire)
Sep-28-21 04:01PM	FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency (GlobeNewswire) -8.44%
Sep-24-21 08:00AM	Catalyst Biosciences to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-17-21 07:06AM	Here's Why We're A Bit Worried About Catalyst Biosciences' (NASDAQ:CBIO) Cash Burn Situation (Simply Wall St.)
Sep-15-21 08:00AM	Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital (GlobeNewswire) +5.64%
Sep-09-21 08:00AM	Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics (GlobeNewswire)
Sep-08-21 08:00AM	Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors (GlobeNewswire)
Aug-05-21 10:55AM	Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-29-21 03:05PM	Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-21 08:00AM	Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies (GlobeNewswire)
Jul-19-21 04:01PM	Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress (GlobeNewswire)
02:09AM	Reflecting on Catalyst Biosciences' (NASDAQ:CBIO) Share Price Returns Over The Last Five Years (Simply Wall St.)
Jul-14-21 08:00AM	Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company (GlobeNewswire) -6.74%
Jul-06-21 08:00AM	Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis (GlobeNewswire)
Jul-01-21 08:00AM	Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs (GlobeNewswire)
Jun-28-21 08:45AM	Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA (Benzinga)
08:00AM	Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency (GlobeNewswire)
Jun-21-21 06:00AM	KBR to Provide Engineering & Technical Services for NATO Allies Patriot System (PR Newswire)
Jun-10-21 08:00AM	Catalyst Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-20-21 02:57AM	What Type Of Shareholders Own The Most Number of Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares? (Simply Wall St.)
May-18-21 08:00AM	Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra (GlobeNewswire)
May-13-21 08:00AM	Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit (GlobeNewswire)
May-06-21 12:19PM	Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat? (Zacks)
09:23AM	Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season? (Zacks)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ma Songjiang	President	May 27 '25	Sale	10.28	2,000	20,560	2,806,642	May 29 04:01 PM
Ma Songjiang	President	May 28 '25	Sale	10.07	558	5,619	2,806,084	May 29 04:01 PM
Ma Songjiang	President	May 22 '25	Sale	10.97	2,000	21,940	2,808,824	May 27 04:02 PM
Ma Songjiang	President	May 23 '25	Sale	10.24	182	1,864	2,808,642	May 27 04:02 PM
Ma Songjiang	President	May 20 '25	Sale	11.25	2,000	22,500	2,812,824	May 22 04:01 PM
Ma Songjiang	President	May 21 '25	Sale	10.83	2,000	21,660	2,810,824	May 22 04:01 PM
Ma Songjiang	President	May 16 '25	Sale	11.31	2,000	22,620	2,816,824	May 20 04:01 PM
Ma Songjiang	President	May 19 '25	Sale	11.11	2,000	22,220	2,814,824	May 20 04:01 PM
Ma Songjiang	President	May 15 '25	Sale	10.68	2,000	21,360	2,818,824	May 16 04:01 PM
Ma Songjiang	President	May 14 '25	Sale	11.30	20	226	2,820,824	May 16 04:01 PM
Ye Weiguo	Chief Operating Officer	Apr 01 '25	Option Exercise	0.75	50,000	37,500	700,000	May 14 08:21 PM
Ma Songjiang	President	May 13 '25	Sale	11.37	2,000	22,740	2,820,844	May 14 04:04 PM
Ma Songjiang	President	May 12 '25	Sale	10.56	2,000	21,120	2,822,844	May 14 04:04 PM
Ye Weiguo	Chief Operating Officer	Mar 24 '25	Option Exercise	0.75	300,000	225,000	300,000	Apr 25 04:01 PM
Ye Weiguo	Chief Operating Officer	Mar 26 '25	Option Exercise	0.75	200,000	150,000	500,000	Apr 25 04:01 PM
Ye Weiguo	Chief Operating Officer	Mar 27 '25	Option Exercise	0.75	150,000	112,500	650,000	Apr 25 04:01 PM
Eastling Thomas Wilson	Director	Apr 16 '25	Option Exercise	6.93	15,000	103,950	15,000	Apr 18 05:27 PM
Ma Songjiang	President	Mar 21 '25	Sale	10.00	174	1,740	2,824,844	Mar 25 04:01 PM
Ma Songjiang	President	Mar 19 '25	Sale	10.13	2,000	20,260	2,827,018	Mar 21 04:01 PM
Ma Songjiang	President	Mar 20 '25	Sale	10.09	2,000	20,180	2,825,018	Mar 21 04:01 PM
Ma Songjiang	President	Mar 17 '25	Sale	12.09	2,000	24,180	2,829,260	Mar 19 04:01 PM
Ma Songjiang	President	Mar 18 '25	Sale	10.24	242	2,478	2,829,018	Mar 19 04:01 PM
Ma Songjiang	President	Mar 14 '25	Sale	12.31	2,000	24,620	2,831,260	Mar 17 04:01 PM
Ma Songjiang	President	Mar 13 '25	Sale	11.80	2,000	23,600	2,833,260	Mar 17 04:01 PM
Ma Songjiang	President	Mar 12 '25	Sale	11.74	2,000	23,480	2,835,260	Mar 13 04:01 PM
Ma Songjiang	President	Mar 11 '25	Sale	11.40	2,000	22,800	2,837,260	Mar 13 04:01 PM
Ma Songjiang	President	Mar 07 '25	Sale	10.25	2,000	20,496	2,841,260	Mar 11 04:01 PM
Ma Songjiang	President	Mar 10 '25	Sale	10.14	2,000	20,280	2,839,260	Mar 11 04:01 PM
Ma Songjiang	President	Mar 05 '25	Sale	10.98	2,000	21,960	2,845,260	Mar 07 04:02 PM
Ma Songjiang	President	Mar 06 '25	Sale	10.80	2,000	21,600	2,843,260	Mar 07 04:02 PM
Ma Songjiang	President	Mar 03 '25	Sale	11.23	2,000	22,460	2,849,260	Mar 05 04:01 PM
Ma Songjiang	President	Mar 04 '25	Sale	10.86	2,000	21,720	2,847,260	Mar 05 04:01 PM
Ma Songjiang	President	Feb 28 '25	Sale	11.41	2,000	22,820	2,851,260	Mar 03 04:01 PM
Ma Songjiang	President	Feb 27 '25	Sale	11.33	2,000	22,660	2,853,260	Mar 03 04:01 PM
Ma Songjiang	President	Feb 26 '25	Sale	11.63	2,000	23,260	2,855,260	Feb 27 04:02 PM
Ma Songjiang	President	Feb 25 '25	Sale	11.37	2,000	22,740	2,857,260	Feb 27 04:02 PM
Ma Songjiang	President	Feb 21 '25	Sale	11.91	2,000	23,818	2,861,260	Feb 25 04:01 PM
Ma Songjiang	President	Feb 24 '25	Sale	10.69	2,000	21,372	2,859,260	Feb 25 04:01 PM
Ma Songjiang	President	Feb 20 '25	Sale	12.40	2,000	24,800	2,863,260	Feb 21 04:01 PM
Ma Songjiang	President	Feb 19 '25	Sale	12.29	2,000	24,580	2,865,260	Feb 21 04:01 PM
Ma Songjiang	President	Feb 18 '25	Sale	12.49	2,000	24,980	2,867,260	Feb 19 04:01 PM
Ma Songjiang	President	Feb 14 '25	Sale	11.94	2,000	23,880	2,869,260	Feb 19 04:01 PM
Ma Songjiang	President	Feb 13 '25	Sale	11.69	2,000	23,380	2,871,260	Feb 14 04:00 PM
Ma Songjiang	President	Feb 12 '25	Sale	11.49	2,000	22,980	2,873,260	Feb 14 04:00 PM
Ma Songjiang	President	Feb 10 '25	Sale	11.90	2,000	23,800	2,877,138	Feb 12 08:45 PM
Ma Songjiang	President	Feb 11 '25	Sale	11.52	1,878	21,635	2,875,260	Feb 12 08:45 PM
Ma Songjiang	President	Feb 06 '25	Sale	12.85	2,000	25,700	2,881,138	Feb 11 04:01 PM
Ma Songjiang	President	Feb 07 '25	Sale	12.16	2,000	24,320	2,879,158	Feb 11 04:01 PM
Ma Songjiang	President	Feb 05 '25	Sale	12.39	2,000	24,789	2,883,138	Feb 06 04:01 PM
Ma Songjiang	President	Feb 04 '25	Sale	11.62	2,000	23,240	2,885,138	Feb 06 04:01 PM
Ma Songjiang	President	Jan 31 '25	Sale	11.51	2,000	23,020	2,889,138	Feb 04 04:01 PM
Ma Songjiang	President	Feb 03 '25	Sale	11.47	2,000	22,940	2,887,138	Feb 04 04:01 PM
Ma Songjiang	President	Jan 29 '25	Sale	11.43	2,000	22,860	2,893,138	Jan 31 04:01 PM
Ma Songjiang	President	Jan 30 '25	Sale	11.37	2,000	22,740	2,891,138	Jan 31 04:01 PM
Ma Songjiang	President	Jan 28 '25	Sale	11.51	2,000	23,020	2,895,138	Jan 29 04:01 PM
Ma Songjiang	President	Jan 27 '25	Sale	11.18	2,000	22,360	2,897,138	Jan 29 04:01 PM
Ma Songjiang	President	Jan 24 '25	Sale	10.89	2,000	21,780	2,899,138	Jan 27 04:01 PM
Ma Songjiang	President	Jan 23 '25	Sale	10.49	2,000	20,980	2,901,138	Jan 27 04:01 PM
Ma Songjiang	President	Jan 21 '25	Sale	10.85	2,000	21,700	2,905,138	Jan 24 04:01 PM
Ma Songjiang	President	Jan 22 '25	Sale	10.63	2,000	21,260	2,903,138	Jan 24 04:01 PM
Ma Songjiang	President	Jan 17 '25	Sale	10.72	2,000	21,440	2,907,138	Jan 21 04:01 PM
Ma Songjiang	President	Jan 16 '25	Sale	10.71	2,000	21,420	2,909,138	Jan 21 04:01 PM
Ma Songjiang	President	Jan 15 '25	Sale	10.85	2,000	21,700	2,911,138	Jan 16 04:01 PM
Ma Songjiang	President	Jan 14 '25	Sale	10.39	2,000	20,780	2,913,138	Jan 16 04:01 PM
Ma Songjiang	President	Jan 10 '25	Sale	10.02	1,057	10,591	2,915,194	Jan 14 04:01 PM
Ma Songjiang	President	Jan 13 '25	Sale	10.10	56	566	2,915,138	Jan 14 04:01 PM
Ma Songjiang	President	Jan 07 '25	Sale	10.02	1,275	12,776	2,916,251	Jan 08 04:01 PM
Ma Songjiang	President	Jan 06 '25	Sale	10.16	941	9,561	2,917,526	Jan 08 04:01 PM
Ma Songjiang	President	Jan 02 '25	Sale	12.40	2,000	24,800	2,920,467	Jan 06 04:01 PM
Ma Songjiang	President	Jan 03 '25	Sale	11.03	1,167	12,872	2,919,300	Jan 06 04:01 PM
Ma Songjiang	President	Dec 30 '24	Sale	12.50	2,000	25,000	2,924,467	Jan 02 04:06 PM
Ma Songjiang	President	Dec 31 '24	Sale	12.30	2,000	24,600	2,922,467	Jan 02 04:06 PM
Ma Songjiang	President	Dec 26 '24	Sale	12.70	2,000	25,393	2,928,467	Dec 30 04:01 PM
Ma Songjiang	President	Dec 27 '24	Sale	12.58	2,000	25,160	2,926,467	Dec 30 04:01 PM
Ma Songjiang	President	Dec 23 '24	Sale	12.27	2,000	24,539	2,932,467	Dec 26 04:01 PM
Ma Songjiang	President	Dec 24 '24	Sale	11.93	2,000	23,860	2,930,467	Dec 26 04:01 PM
Ma Songjiang	President	Dec 20 '24	Sale	10.90	2,000	21,800	2,934,467	Dec 23 04:01 PM
Ma Songjiang	President	Dec 19 '24	Sale	10.82	2,000	21,640	2,936,467	Dec 23 04:01 PM
Ma Songjiang	President	Dec 18 '24	Sale	11.37	2,000	22,743	2,938,467	Dec 19 04:01 PM
Ma Songjiang	President	Dec 17 '24	Sale	11.05	2,000	22,109	2,940,467	Dec 19 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GYRE

Gyre Therapeutics Inc

Upgrade your FINVIZ experience